2Malaguarnera G,Giordano M,Paladina I. Serum markers of hepatocellular carcinoma[J].Digestive Diseases and Sciences,2010,(10):2744-2755.
3Treska V,Topolcan O,Vrzalov J. Can tumor markers predict outcomes of portal vein branch embolization in patients with primary inoperable liver tumors[J].Rozhledy v Chirurgii,2011,(05):285-289.
4Wu X,Lu XH,Xu T. Evaluation of the diagnostic value of serum tumor markers,and fecal k-ras and p53 gene mutations for pancreatic cancer[J].International Journal of Digestive Disease,2006,(03):170-174.
5Lu XY,Xi T,Lau W Y. Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J].Annals of Surgical Oncology,2011,(08):2210-2217.
6Ju MJ,Qiu SJ,Fan J. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation[J].Journal of Gastroenterology,2009,(06):635-642.doi:10.1007/s00535-009-0050-x.
3Pritzker KH. Cancer biomarkers : easier said than done. Clin Chem, 2002,48: 1147- 1150.
4Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic. Washington DC: AACC Press,2002.20-25
6Lakhani SR, Ashworth A. Microarray and histo-pathological analysis of tumours:the future and the past? Nature Rev Cancer, 2001,1:151-157.
7Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer benign breast disease and normal breast tissue. Breast Cancer Res Treat, 1996,40:171- 178.
8Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 2003,3:267-275.
9Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer, 2002, 2:210-219.
10Sun X, Hung K, Wu L, et al. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nat Biotechol, 2002,20:186-189.
